Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 21, 2015The EPMA JournalOpen Access

May CTC technologies promote better cancer management?

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMartin PeštaCharles UniversityVKVlastimil KuldaCharles UniversityAŇAndrea Ňaršanská

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pešta et al. (2015) studied this question.

synapsesocial.com/papers/6a9010fdb71d06dae589d0c4https://doi.org/10.1186/s13167-014-0023-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer2012 · 227 citations
  2. 2Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases2004 · 2,545 citations
  3. 3Revised Tumor and Node Categorization for Rectal Cancer Based on Surveillance, Epidemiology, and End Results and Rectal Pooled Analysis Outcomes2009 · 244 citations
  4. 4Prevalence and Heterogeneity of <i>KRAS, BRAF</i>, and <i>PIK3CA</i> Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases2010 · 434 citations
  5. 5Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients2011 · 239 citations